HMGCR and lung cancer: In terms of lung cancer, the intake of genetically predicted antithrombotic agents (OR = 0.67; 95% CI = 0.54–0.83, P = 0.0003), antihypertensives (OR = 0.80; 95% CI = 0.68–0.94, P = 0.007), salicylic acid and derivatives (OR = 0.75; 95% CI = 0.59–0.95, P = 0.018), HMG CoA reductase inhibitors (OR = 0.91; 95% CI = 0.84–0.99, P = 0.026) and thyroid preparations (OR = 0.90; 95% CI = 0.86–0.95, P = 0.00006) intake decreased the odds.